Aeglea BioTherapeutics - AGLE Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGLE shares.
View AGLE analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month target prices for Aeglea BioTherapeutics' stock. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $1.88 in the next twelve months. This suggests a possible upside of 468.2% from the stock's current price.
View analysts price targets for AGLE or view top-rated stocks among Wall Street analysts.

Aeglea BioTherapeutics' stock was trading at $0.4499 at the beginning of the year. Since then, AGLE stock has decreased by 26.7% and is now trading at $0.33.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AGLE earnings forecast.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03. The biotechnology company earned $1.40 million during the quarter, compared to analyst estimates of $1.38 million. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 127.15% and a negative net margin of 3,598.75%.

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Aeglea BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (7.50%), Millennium Management LLC (5.09%), Pura Vida Investments LLC (1.70%), Geode Capital Management LLC (0.98%), Sphera Funds Management LTD. (0.72%) and Two Sigma Investments LP (0.64%). Insiders that own company stock include Anthony G Quinn, Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza.
View institutional ownership trends.

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGLE stock can currently be purchased for approximately $0.33.

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $21.58 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

The company employs 101 workers across the globe.

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.